

TABLE OF CONTENTS

OPENING REMARKS

Dr D. H. Calam, Chair of the European Pharmacopoeia Commission

SESSION I: LOOKING BACK AT 4 YEARS' PHARMACOPOEIAL WORK:

Recent Changes in the European Pharmacopoeia

Mr P. Castle, Secretary to the European Pharmacopoeia Commission

Dr D. H. Calam, Chair of the European Pharmacopoeia Commission

Experience and practical viewpoint of an OMCL

Dr M. Wierer, Landesinstitut für den öffentlichen Gesundheitsdienst Nordrhein-Westfalen
Arzneimitteluntersuchungsstelle (Münster - Germany)

Discussion Session I

SESSION II: SETTING CONTENT LIMIT / ACCEPTANCE OF ANALYTICAL RESULTS:

Challenging the principles of setting limits in pharmacopoeial tests

Prof. S. H. Hansen, Royal Danish School of Pharmacy, Department of Analytical & Pharmaceutical Chemistry (Copenhagen - Denmark)

Limits for setting limits

Dr M. Weber, EMPA (St Gallen - Switzerland)

How to set up specifications for new chemical entities during preclinical and clinical phases

Mr M. Bauer, Sanofi Synthelabo Centre de Recherche, Département International d'Analyses
(Toulouse - France)

Discussion Session II

TOPIC 1: USE, ESTABLISHMENT AND ASSIGNED VALUE OF REFERENCE SUBSTANCES

Use of reference substances in the analytical control laboratory:

Needs for innovative pharmaceutical industry

Dr A. Brutsche, Novartis Pharma, (Stein - Switzerland)

Needs for generic pharmaceutical industry

Dr A. Rotar, KRKA d.d., (Novo Mesto - Slovenia)

Needs for regulation and inspection

Dr G. Lee, Medicines Control Agency (MCA), (London - Great Britain)

Discussion

Present Policy of the European Pharmacopoeia for the different categories concerned:

Chemical Reference Substances (CRS):

Role of the EDQM in organising collaborative studies/assigned value/uncertainty

Dr J. Miller, Head of Laboratory, EDQM (Strasbourg – France)

Standards - the key to effective analytical measurement performance

Dr K. J. Leiper, Benson Associates (Grantham - Great Britain)

Discussion

Establishment of the reference material: How to elaborate a CRS?

Role of the industry in the establishment of a CRS

Mr J. van Rompay, Janssen Research Foundation, (Beerse-Belgium)

Role and responsibilities of an OMCL in establishing reference substances:

Background and practical experience from the participation

Dr P. Helboe, Danish Medicines Agency (DKMA), (Copenhagen-Denmark)

Discussion

CRS impurities. When? How?

Dr F. Erni, Novartis Pharma, (Basel - Switzerland)

General Discussion:

TOPIC 2: NEW AND EMERGING TECHNIQUES

Advanced chromatographic and electrophoretic methods for testing enantiomeric purity

Prof. Dr G. Blaschke, Institute of Pharmaceutical Chemistry (Münster - Germany)

General aspects of the near infrared spectrometry technique. Validation and comparison with traditional wet chemistry of the Ph. Eur. methods

Mr A. C. M. Gerich, Organon NV, (Oss - The Netherlands)

Using near infrared spectrometry in an OMCL

Dr D. De Kaste, National Institute for Public Health and the Environment (RIVM), (Bilthoven - The Netherlands)

Raman spectrometry - an emerging technique with exciting possibilities

Dr C. E. Sjøgren, Nycomed Amersham Imaging AS, (Oslo- Norway)

Liquid Chromatography – Mass Spectrometry for identification of drug impurities

Dr L. Tollsten, AstraZeneca R&D, (Möln dal – Sweden)

In process control versus testing the finished product

Prof. C. Graffner, Medical Products Agency, (Uppsala - Sweden)

Towards parametric release in pharmaceutical production: Process analytical chemistry paves the way

Prof. S. Folestad, AstraZeneca R&D, (Möln dal - Sweden)

The practical applications of the Ph. Eur. excipient monographs in the industry? 61

Dr V. Bühler, BASF AG (Ludwigshaffen - Germany)

New excipients and new methods to characterise excipients

Prof. H. J. De Jong, Institut de Recherches Internationales Servier and IPEC-Europe

Discussion

SESSION III: SEPARATION TECHNIQUES

Latest developments of general separation methods

Prof. Dr S. Ebel, Department of Pharmacy, University(Würzburg - Germany)

Process vs. Performance control in HPLC; Characterisation of columns and instrumentation

Prof. Dr H. Engelhardt, Universität des Saarlandes, (Saarbrücken - Germany)

Adjustment of chromatographic conditions/ permitted variability

Dr G. Houghton, Medicines Control Agency (MCA), (London - Great Britain)

System performance and variability of chromatographic techniques used in pharmaceutical quality control

Dr B. Renger, Byk Gulden, (Konstanz - Germany)

Equipment qualification and revalidation of analytical procedure

Dr J. Ermer, Aventis Pharma, (Frankfurt - Germany)

Are presently prescribed system suitability requirements sufficient?

Prof. Dr J. Hoogmartens, Katholieke Universiteit Leuven, (Leuven - Belgium)

Round table discussion

SESSION IV: PROSPECTIVE AND EXPECTATIONS

Inorganic impurities in pharmaceutical preparations/ origin, relevance, and consequences for pharmacopoeial monographs

Dr D. Jäkel, Novartis Pharma (Stein - Switzerland)

Control of medicines: link between registration authorities OMCL's and Pharmacopoeias

Dr J. L. Robert, OMCL and Chair Joint CPMP/CVMP Quality Working Party (EMEA)

Round table discussion: Prospective and expectations from the users

Biographical notes

Final List of Participants